Mei Ri Jing Ji Xin Wen·2025-09-15 10:47Core Viewpoint - Baiyunshan (600332.SH) announced that its subsidiary Baiyunshan Pharmaceutical Factory received feedback from the National Medical Products Administration, allowing the application for a Phase II single-arm clinical trial for the selective RET small molecule inhibitor BYS10 tablets, which are intended for the treatment of advanced solid tumors such as non-small cell lung cancer and medullary thyroid carcinoma [1] Company Summary - BYS10 tablets are currently the only drug of its kind in development in China, with no similar drugs registered or approved domestically or internationally [1] - As of August 2025, the project has incurred research and development expenses amounting to RMB 146.0935 million [1] - The company acknowledges the inherent uncertainties in innovative drug development, indicating that future R&D expenses are expected to increase, but these will not significantly impact the company's financial status and operating results in the short term [1]